July 14,2006
Chairman Grassley Questions CMS, FDA About Substituted Inhalation Drugs
Please see the printer-friendly version of Chairman Grassley's letter CMS and FDA regarding substituted inhalation drugs.
Next Article Previous Article
Recent News
- Crapo Statement at IRS Commissioner Nomination Hearing
- Finance Committee Advances HHS Nominations
- Crapo Statement at Executive Session to Consider HHS Nominations
- Crapo Applauds House Committee Markups Advancing President Trump’s Economic Agenda
- Crapo Statement at Hearing on Trade in Critical Supply Chains